Introduction
Raltegravir has demonstrated good tolerability and efficacy in treatment-naive patients and treatment-experienced individuals. However, data on liver safety in HIV/hepatitis C virus (HCV) co-infection are limited and conflicting. Thus, in the Blocking Integrase in Treatment Experienced Patients with a Novel Compound against HIV, Merck (BENCHMRK) 1 and 2 clinical trials, the incidence of asymptomatic grade 3 or 4 alanine aminotransferase (ALT) elevations in the hepatitis B virus (HBV) and/or HCV co-infected subpopulation was 8 cases per 100 person-years. 1 In contrast, in a recent cohort study, the global frequency of grade 3-4 transaminase elevations (TEs) was 1.4% and 3.3% for the HCV co-infected subpopulation. 2 These contradictory data need clarification. Furthermore, the risk of severe TEs in co-infected patients with significant fibrosis or cirrhosis has not been established. The primary aim of this study was to determine the liver safety of antiretroviral drug therapy (ART) including raltegravir in HIV/HCV co-infected patients. The secondary aim was to evaluate the relationship of grade 3 or 4 TEs and grade 4 total bilirubin elevations (TBEs) with liver fibrosis.
Patients and methods

Study design and patients
The HEPRAL study was a retrospective cohort study that included patients attending 12 Spanish hospitals between June 2007 and August 2009 and who fulfilled the following criteria: (i) starting ART that included raltegravir; (ii) older than 18 years; (iii) at least 1 week of continued ART; and (iv) chronic HCV infection as confirmed by the demonstration of HCV RNA in serum by PCR. Patients were excluded if they had other liver diseases or if they started treatment against HCV infection during the follow-up. Clinical visits and blood tests were carried out at baseline, at month 1, at month 3 and every 3 months afterwards. The total follow-up period was 12 months or the timepoint of raltegravir discontinuation.
Definition of liver toxicity
In patients with normal baseline levels of ALT and AST, values of ALT or AST 5 -10 times the upper level of normality (ULN) were considered grade 3 TEs, while grade 4 TE was defined as ALT or AST values .10 times the ULN. When patients presented elevated baseline ALT or AST levels, an elevation between 3.5-and 5-fold was considered grade 3 TEs and a .5-fold elevation grade 4 TEs. Grade 4 TBEs were defined as total bilirubin levels .5 times the ULN.
Assessment of liver fibrosis
Liver fibrosis was assessed according to a stepwise algorithm including liver biopsy, hepatic transient elastometry and blood biomarkers. This algorithm has been described elsewhere. 3 
Statistical analysis
The outcome variables were grade 3 or 4 TEs and grade 4 TBEs. Continuous variables were compared using Student's t-test for normal distribution and the Mann-Whitney U-test otherwise. Categorical variables were analysed with the x 2 test or Fisher's test, when applicable. For repeated measures, the Wilcoxon signed rank test was applied for continuous measurements and the McNemar test for categorical ones. A logistic regression model was elaborated to identify independent risk factors for TEs and TBEs. All variables with a univariate P,0.2 and those with a biologically possible influence were entered in a single step. All P values ,0.05 were considered statistically significant.
Ethical aspects
The study was designed and performed according to the Helsinki declaration and was approved by the Ethics Committee of the Hospital Universitario de Valme.
Results
Characteristics of the study population
One hundred and eight patients met the inclusion criteria. The baseline characteristics are listed in Table 1 . Patients were followed for a median time (Q1 -Q3) of 12.1 (11.3 -13) months. Seven (6.5%) patients discontinued raltegravir: three (2.8%) voluntarily dropped out; two (1.9%) discontinued because of virological failure; and two (1.9%) died of a non-hepatic reason.
The median (Q1 -Q3) CD4 cell count increased from 257 (145 -421) cells/mm 3 at baseline to 407 (213-587) cells/mm 3 at the end of follow-up (P,0.0001). The number of patients with an undetectable HIV viral load was 33 (30.6%) at baseline and 73 (81.1%) at the end of follow-up (P,0.0001).
Liver events
No patient permanently discontinued raltegravir because of liver toxicity. Macías et al.
three (30%) patients, at 3 months in four patients (40%), at 6 months in two patients (20%) and at 12 months in one patient (10%).
Four (3.7%) patients had hepatic decompensations during the follow-up, three (2.8%) showed ascites and one (0.9%) hepatocellular carcinoma. All of these patients had already shown these decompensations before starting treatment with raltegravir. No patients among those who presented grade 3 -4 TEs also had a decompensation of cirrhosis.
Grade 4 TBEs were detected in two (1.9%, 95% CI 20.7%, 4.4%) patients, one at week 4 and the other at week 12 after raltegravir initiation. There were no concomitant hepatic decompensations along with grade 4 TBEs. One case of TBEs simultaneously emerged with grade 4 TEs 3 months after raltegravir-containing ART initiation, with spontaneous resolution at the following visit without treatment interruption.
Univariate associations with grade 3 -4 TEs and grade 4 TBEs are shown in Table 2 . No independent predictor of grade 3-4 TEs or grade 4 TBEs was found in the multivariate analysis.
Discussion
Raltegravir is generally safe in HIV-infected patients with chronic hepatitis C, as shown in this cohort study. The incidence of grade 3 -4 TEs and of grade 4 TBEs among HIV/HCV co-infected patients after starting raltegravir-based regimens was within the range observed for ritonavir-boosted protease inhibitors (PI/r) in clinical trials among co-infected patients. No treatment discontinuations due to liver toxicity were observed. This is a remarkable finding as HIV/HCV co-infected individuals starting nevirapine, efavirenz or PI/r-based regimens show higher discontinuation rates. 4 In addition, the presence of significant liver fibrosis did not increase the risk of severe TEs associated with ART-containing raltegravir.
In a recent cohort study by Vispo et al., 2 grade 3 -4 TEs were only seen in 3.3% of HCV co-infected individuals. In contrast, the incidence of grade 3-4 ALT elevations found in the BENCHMRK-1 and BENCHMRK-2 clinical trials was 8 cases per 100 person-years for the HBV and/or HCV co-infected subpopulation. 1 However, the number of co-infected patients included in these trials was relatively low. Furthermore, visits are more frequent in clinical trials, allowing the detection of more laboratory abnormalities. In our retrospective study, the prevalence of TEs was 9.3% in the first year of follow-up, thus being in agreement with that observed in the BENCHMRK clinical trials.
Liver safety analyses on PI/r in clinical trials among HIV/hepatitis virus co-infected patients have reported an incidence of grade 3 -4 TEs between 6% and 15%. 5 -7 The incidence of severe TEs of nevirapine and efavirenz in HIV/HCV co-infected individuals in a cohort study was 11% for nevirapine and 6% for efavirenz. 4 The frequency of severe TEs associated with raltegravir-based ART in the present study was within the range observed for PI/r in clinical trials among co-infected subjects. Importantly, the discontinuation rates among HIV/HCV co-infected individuals starting ART were 13% for nevirapine, 4% for efavirenz and 6% for PI/r-based regimens. 4 In contrast, no co-infected patient starting raltegravir-based regimens discontinued therapy in the present study.
In this study, there was no association between grade 3 -4 TEs and baseline significant fibrosis (fibrosis stage ≥2). However, there are studies that found an influence of preexisting fibrosis on the incidence of ART-induced liver toxicity. 8, 9 In contrast, more recent studies on PI/r in HIV/HCV co-infected patients have reported no statistically significant difference between patients with and without significant fibrosis at baseline. 3, 10 These findings are comparable to the results reported here. We therefore conclude that raltegravir-containing combinations are a safe option in HIV/HCV co-infected patients with fibrosis stage ≥2.
HIV-infected patients with chronic hepatitis C are at risk of developing cirrhosis. The presence of cirrhosis may cause metabolic alterations and lead to overexposure to antiretroviral drugs. Therefore, data on the liver safety profile of antiretroviral drugs in cirrhotics is needed. In this study, there was no statistical difference between patients with and without cirrhosis showing grade 3 -4 TEs or grade 4 TBEs. Our results suggest that raltegravir can be considered safe in cirrhotics. Raltegravir metabolism via glucuronidation, less prone to be affected by liver insufficiency, might account for this safety.
This study has some limitations. Firstly, patients were not seen in this retrospective study as frequently as they were in clinical trials. Thus, transient laboratory abnormalities may not have been noticed. However, patients were only included if they had followed a strictly defined visiting schedule. It is therefore unlikely that the prevalence of clinically relevant hepatotoxic events was underestimated. Secondly, fibrosis assessment was not possible in all patients. However, the majority of patients could be classified and can therefore be regarded as representative of the whole study population. Thirdly, fibrosis was assessed using different methods. Nevertheless, it has been demonstrated that there is a high correlation between liver biopsy and transient elastometry. Furthermore, it has been shown that the blood biomarkers used in the present study have a high positive predictive value for fibrosis stage ≥2.
In conclusion, the liver tolerance of raltegravir in HIV/HCV co-infected patients in real-life conditions of use is good and similar to that reported in clinical trials. Raltegravir is a safe option for co-infected patients with fibrosis stage ≥2 or cirrhosis. Therefore, regimens including raltegravir are adequate for patients with HIV/HCV co-infection, including those with advanced liver disease.
